Trygve H.
- Country
- Norway
- Department
- Department of Neurology
Research Overview
- Comparative Efficacy and Safety of Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine, or Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
- Investigation of Intrathecal Autologous Mesenchymal Stromal Cells for Neuroregeneration in Progressive Multiple Sclerosis: A Controlled Clinical Trial
Data & Insights
Has run more than one trial at 4 of 7 partner sites.
Specializations
Neurological Disorders
This investigator specializes in treating multiple sclerosis, with particular emphasis on innovative therapeutic approaches for both relapsing-remitting and progressive forms of the disease.
- Relapsing-Remitting Multiple Sclerosis
- Progressive Multiple Sclerosis
- Neuroregenerative Therapy
The investigator focuses on evaluating advanced treatment options including stem cell therapies and comparative treatment assessments.
Cell-Based Therapies
Expertise in autologous cell treatments, particularly focusing on mesenchymal stem cell applications and hematopoietic stem cell transplantation for neurological conditions.
- Mesenchymal Stem Cell Therapy
- Intrathecal Treatment Applications
- Hematopoietic Stem Cell Transplantation
The investigator explores innovative cellular therapeutic approaches for treating aggressive forms of multiple sclerosis.
Therapeutic Assessment
Specialized in evaluating neurophysiological parameters and treatment outcomes in multiple sclerosis patients, with focus on comparative therapeutic efficacy.
- Treatment Efficacy Analysis
- Safety Assessment Protocols
- Comparative Treatment Studies
The investigator conducts comprehensive evaluations of various treatment modalities for multiple sclerosis management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.